Bleomycin Sulfate

Catalog No.S1214 Synonyms: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
USD 170 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrxSmVWOOLCk{GwNFAh|ryv MlOwNlQhcMLi M{TJcolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NGj2cZkzPjB6OEexNS=>
POLK WT M1zOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\0dFVXUUN3ME2xNU446oDLwsJihKkyNjgEoN88US=> MkTENlYxOzF2MEC=
POLK KO MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXtTWM2OD12LkCz5qCKyrIkgJmxMlkzyqEQvF2= NIfnd3UzPjB|MUSwNC=>
POLK CD MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HP[WlEPTB;NT61PgKBkcLz4pEJNU4xOMLizszN NGrHSWIzPjB|MUSwNC=>
RLE/Abca3 MkjxSpVv[3Srb36gRZN{[Xl? MUGwMlTDqM7:TR?= MofzNVQ1yqCq M1zBbYlv\HWlZYOgZUBud3KyaH;sc4dq[2GuIHPoZY5o\SCocn;tJIVxcXSqZXzpZYwudGmtZTDtc5JxcG:ub3f5JJRwKGFid3nk[Uwhe3C{ZXHkMY92fCCvb4LwbI9td2e7wrC= M3O0PFI2PzZyNUO4
PMCs NV\GcoVCTnWwY4Tpc44hSXO|YYm= NYrJ[JNYOC5z4pETNuKh|rypL33s MkHGNlTDqGh? MWDjZZV{\XNiYTDkc5NmNWSncHXu[IVvfCCrbnPy[YF{\SCrbjD0bIUheHKxdHXpckBt\X[nbDDv[kBkd2yuYXflck1KyqB? M3PEeVI2PTl3NkSy
PMCs MWXGeY5kfGmxbjDBd5NigQ>? NGDi[4wxNjMEoN88[{9udA>? MlLENlTjiJN5MtMgbC=> NWDCPYg5cW6mdXPld{BqdmO{ZXHz[ZMhcW5idnnt[Y51cW5iYX7kJO6yNVOPQTDwdo91\Wmw MnnWNlU2QTV4NEK=
PMCs NGLsWmRHfW6ldHnvckBCe3OjeR?= Mm\wNE4zyqEQvHevcYw> MWi3NkBp MmjPbY5lfWOnczDk[YNz\WG|ZYOgbY4h[3m2b3vldoF1cW5vODDhcoQhTS2lYXTo[ZJqdiCycn;0[Ylv NHjTT|UzPTV7NU[0Ni=>
PMCs MYPGeY5kfGmxbjDBd5NigQ>? NITRbmsxNjMEoN88[{9udA>? NUnTe4hwOTJxMkSvOFghcA>? M2XKRolv[3KnYYPld{Bk\WyuIH3p[5JifGmxbh?= MYmyOVU6PTZ2Mh?=
IMR-32 NXnhc5FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{myW|cvPeLKkkGyNEDDvWdxbXy= NYXnb|Y2OTMkiKK0PEBp M4nFOmlEPTB;NkCgxtVoN22uIHH0JJRp\SCnbnSgc4YhOjRiaILzJI9nKGmwY4XiZZRqd25? NVjRO402OjV3M{[zOFU>
HT1080 NEHWfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTyPGkyKM7:TR?= M{jNZVI1KGkEoB?= NHPNbFBt\WGmczD0c{BiKEd{L12g[IVt[Xl? M3nMd|I2PTF6OU[x
HT1080 M4n6TWZ2dmO2aX;uJGF{e2G7 MXexJO69VQ>? MV:yOEBpyqB? NYnLXIJtcW6mdXPld{BiKHCxdHXueEBodG:kYXygSG5CKGSjbXHn[UBz\XOyb37z[S=> M4DJWVI2PTF6OU[x
HDFn M130SWN6fG:2b4jpZ4l1gSCDc4PhfS=> NX3YWpptPzJiaB?= Ml2wTWM2OD17LkOxKeKh MkPyNlUzPzZ5OUK=
THP-1 M4nFSWN6fG:2b4jpZ4l1gSCDc4PhfS=> NGjCRXc4OiCq NXiwRYJtUUN3ME20Mlc4LQ>? NV\3fo5ZOjV{N{[3PVI>
HT-29 MXXDfZRwfG:6aXPpeJkhSXO|YYm= NH\pbIo4OiCq M162d2lEPTB;MUGuOFkm NVi4PI5KOjV{N{[3PVI>
HCT116  M1i2dWN6fG:2b4jpZ4l1gSCDc4PhfS=> M3\XUlczKGh? NVLEPJdvUUN3ME2xNU4{PCV? MX[yOVI4Pjd7Mh?=
A431 M4nVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDJNZk2OC1{MECgTXU> NWnKW2hDPDkkgJno MXLpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NWTxbGxZOjVzMEGyPVk>
T24 NFLqU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXu1NE0zODBiSWW= MYS0PQKBkWh? NV2zZVlQcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M3n3N|I2OTBzMkm5
AY-27  MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzHdlg5PTBvMkCwJGlW MorFOFjjiImq MUDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MnzPNlUyODF{OUm=
A549 NHL5bmJHfW6ldHnvckBCe3OjeR?= MoLLNUDDvWdxbV|CpC=> NX7PfW05OC12ODDo NXm0U|hKcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nyqCRUF9CpI1TVkF? NHvZTXIzPDl4M{[zOS=>
MLE12 M4nkS2Z2dmO2aX;uJGF{e2G7 NXS2NHVGOSEEtXevcWzDqA>? MlzLNE01QCCq NFvMNG5qdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4bDqE:STtMgcXJPSQ>? MUSyOFk3OzZ|NR?=
Jurkat NW\qbWJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG0WoQzOOLCid88cS=> Ml\HNlTjiImqwrC= MofDZZJz\XO2czD0bIUh[2WubDDjfYNt\SCjdDD0bIUhTzJicHjhd4U> MXKyOFkyPjh7Mx?=
HeLa  NI\qdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGntUGNKSzVyPUGwMlLDqM7:TR?= MnTJNlQ4OzJ|OUe=
C18-4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z4VVAuOTByIN88US=> NF;STGVqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NV\PfZJtOjR3N{G5PFI>
BMG-1  M1fQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf3N|I1OC96MNMg{txoN21? NEXibpo{yqCq MlzVbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MWqyN|kxPjd{Nh?=
A459 NEXPTnlCeG:ydH;zbZMhSXO|YYm= NVPD[I9EOTBibWW= M3XMb|Q5KGh? NXHubWxlcW6mdXPld{BieG:ydH;zbZM> M2fDUFI{QTB{N{[2
MOCK MXXBdI9xfG:|aYOgRZN{[Xl? NGnxZVkyOCCvVR?= M{GyV|Q5KGh? MYXpcoR2[2W|IHHwc5B1d3Orcx?= NWDkPWRkOjN7MEK3OlY>
MMP1 Mn;lRZBweHSxc3nzJGF{e2G7 MVuxNEBuXQ>? NHjSdGc1QCCq M2fIS4lv\HWlZYOgZZBweHSxc3nz MmHDNlM6ODJ5Nk[=
A549 NHf5T3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfa[VFQOjByIN88US=> M3PrVlI1KGkEoB?= MYfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> M2e2eFI{QDB3N{mz
HCT-116 NEez[29CeG:ydH;zbZMhSXO|YYm= MWqzM|cvPS9zNTFOwIcwdWx? NHrjOm81QCCq MYDy[YR2[2W|IITo[UBt\X[nbDDv[kBDVEhiYYSgbIlocCClb37j[Y51emG2aX;u MoriNlM4ODh4Nki=
HeLa NE\u[JVCeG:ydH;zbZMhSXO|YYm= M2LFN|MwPy53L{G1JO69\y:vbB?= M4\kdlQ5KGh? NIjPV2Nz\WS3Y3XzJJRp\SCuZY\lcEBw\iCETFigZZQhcGmpaDDjc45k\W62cnH0bY9v NY\Dbo5COjN5MEi2Olg>
HCT116 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInPeZQxNTFyMDFOwIcwdWx? NX7tNmlDPDhiaB?= NFjEbnBqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 Mk\tNlM2OTh{MEG=
NCM460 NEPTSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\PNE0yODBizsznM41t MXi0PEBp NHrkdZlqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NHHSTlUzOzVzOEKwNS=>
NT2  NWLuSGNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPTV3kzPCCqwrC= M2TCU2xFPTB;NECw5qCKyrWpL33s MmrvNlM{QDZ2MkC=
NT2  MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHuxeHc1QCCq M3Hl[mxFPTB;MUCwJOK2\y:vbB?= MlvBNlM{QDZ2MkC=
NT2  MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTEO|IhcA>? M1;Zd2xFPTB;MkFihKnDvWdxbXy= NUXUVYdJOjN|OE[0NlA>
NT2  NWfyN2pYSXCxcITvd4l{KEG|c3H5 NUjBZoNCPDBy4pEJxtVoN22u M3rme|I1KGkEoB?= MkGxbY5lfWOnczDzbYdvcW[rY3HueEBqdmO{ZXHz[ZMhcW5iY3HzdIF{\S1|LEisPUBi[3Srdnn0feKh M4jubFI{Ozh4NEKw
NTera-2 NH3tS25HfW6ldHnvckBCe3OjeR?= NYfzXnZbOTJyIN88[{9udA>? Mom1O|IhcA>? Ml\Yd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiOD3pd49xem:|dHHu[UBt\X[nbIO= MX2yNlgzPTN3NR?=
NCCIT Mmi2SpVv[3Srb36gRZN{[Xl? M{HafFEzOCEQvHevcYw> MWS3NkBp NXH0N|FHe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgPE1qe2:ycn;zeIFv\SCuZY\lcJM> MUWyNlgzPTN3NR?=
NTera-2 MkniSpVv[3Srb36gRZN{[Xl? Mkf4NVIxKM7:Zz;tcC=> MXi3NkBp MUTzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCWQlHSV{Bt\X[nbIO= NUDsTVA6OjJ6MkWzOVU>
NCCIT NVTUN41LTnWwY4Tpc44hSXO|YYm= MmDGNVIxKM7:Zz;tcC=> NYrLR4NwPzJiaB?= M4DKepNq\26rZnnjZY51dHliaX7jdoVie2W|IGTCRXJUKGyndnXsdy=> MXeyNlgzPTN3NR?=
NCCIT NV7PfXdbTnWwY4Tpc44hSXO|YYm= NHrRb4kyOjBizsznM41t NVTvZnB{PzJiaB?= NYnzeo1We2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgS3NJKGyndnXsdy=> Ml3PNlI5OjV|NUW=
NTera-2 NVXxOnVqTnWwY4Tpc44hSXO|YYm= M1izcVEzOCEQvHevcYw> MX[3NkBp M1f3SpNq\26rZnnjZY51dHliaX7jdoVie2W|IGDyc5RmcW5iY3HyZo9vgWxibHX2[Yx{ M3zrVFIzQDJ3M{W1
NCCIT NF23cZNHfW6ldHnvckBCe3OjeR?= MlnyNVIxKM7:Zz;tcC=> NUDIdnNOPzJiaB?= MYTzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCScn;0[YlvKGOjcnLvcpltKGyndnXsdy=> NUfydVQ3OjJ6MkWzOVU>
NTera-2 NUWyWm1NTnWwY4Tpc44hSXO|YYm= MWSxNlAh|rypL33s M3HM[FczKGh? MYDzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCOUF:gcIV3\Wy| Mn;RNlI5OjV|NUW=
NCCIT M361PWZ2dmO2aX;uJGF{e2G7 MYOxNlAh|rypL33s NYTYV5ZrPzJiaB?= MVrzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCOUF:gcIV3\Wy| MoLvNlI5OjV|NUW=
MDA-MB-468 M3\zPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fM[|DjiJN{MEFCpO69\y:vTB?= NFv3S48zPCCq Mo\MbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MkXtNlI5OTlzOU[=
231-H2N MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG0Sokx6oDVMkCwxsDPxGdxbVy= MnvCNlQhcA>? MW\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MVqyNlgyQTF7Nh?=
A549  M4nONmZ2dmO2aX;uJGF{e2G7 MmHHNlAxNzRyMDFOwG0> NH3DXpRz\XO3bITzJIlvKGFiZH;z[U1z\XOyb37zbZZmKGmwY4LlZZNmKGmwIGLPVy=> MlHtNlI4PzN4OUe=
A549  M2rGUmZ2dmO2aX;uJGF{e2G7 NGfDXHoxNTRyMDFOwG0> M4fsZlIuPDhiaB?= NEnoc4Fk[XW|ZYOgcY9z\SCvdFTORUB1cGGwIH7EUmEh\GGvYXfl NHnjUWUzOjd5M{[5Oy=>
A549  NXHYNohNTnWwY4Tpc44hSXO|YYm= MmjDNVAxKM7:TdMg MYiw5qCUPDhiaB?= NE\6VY1k[XW|ZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> NHnYUpgzOjd5M{[5Oy=>
A549  NFLqb3VHfW6ldHnvckBCe3OjeR?= NHjyUZkyODBizszNxsA> MUKw5qCUPDhiaB?= MXfjZZV{\XNiUFvENUBkdGWjdnHn[S=> NGjnSoUzOjd5M{[5Oy=>
A549  MV3GeY5kfGmxbjDBd5NigQ>? NF;xN48yODBizszNxsA> MYKw5qCUPDhiaB?= MYDjZZV{\XNibXn0c4Npd26mcnnhcEBtd2OjbHn6ZZRqd25ib3[gRoF5 M2PsfFIzPzd|Nkm3
A549  NUn2V2cyTnWwY4Tpc44hSXO|YYm= M1jYdFExOCEQvF5CpC=> Mn2yNQKBmzR6IHi= MmjS[IVkemWjc3XzJG1OWCCjbnSgRXRRKGyndnXsdy=> NHPVXXgzOjd5M{[5Oy=>
MCF-7/Her-18  M{\QW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Xy[FAvPDJvMUewNEDPxGdxbVy= NWHBR2luOjRiaB?= MUjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NFP2bJAzOjZ{MUSwOC=>
MCF-7 M1XZZ3BFXC:SQ1mgWJJm[XSvZX70 NFm0RYUxNjJ3IN88[{9udC5? NHXrUpIyNTRiaB?= M2LqUpNpd3e|IIPp[45q\mmlYX70JEhRyqB:IECuNFUqKGO7dH;0c5hq[yCnZn\lZ5Q> M37NdFIzPTlzMki0
MDA-MB-231 MY\QSHQwWEOLIGTy[YF1dWWwdB?= MljqNE4zPSEQvHevcYwv M4fVbFEuPCCq MYfzbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 M2XpPVIzPTlzMki0
MDA-MB-235  MoXPVGRVN1CFSTDUdoVifG2nboS= M3flflAvOjVizsznM41tNg>? MX2xMVQhcA>? Ml;Jd4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> NFPkOYwzOjV7MUK4OC=>
MCF-7 M3q5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzqZmIxNTJizsznM41tNg>? Mm\wNlQwPDhiaB?= NFG4SXhGSzVyPUGuNkDPxGdxbVy= MkH6NlI2QTF{OES=
NCCIT  MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\KNlDjiJNzNEFCpO69\y:vbB?= M3;vdFczKGh? MnWyUGQ2OD1zMkFCpO69\y:vbNMg NWWwcVF4OjJ3NkKxOlA>
NCCIT  NWnaZlZITnWwY4Tpc44hSXO|YYm= NEDNbI44OiCq NX36cYRCe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5xsA> NFX2e5czOjV4MkG2NC=>
NCCIT  M1jtRmZ2dmO2aX;uJGF{e2G7 NVrKSm1qPzJiaB?= M2DiZpNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvODDhZ5Rqfmm2edMg Ml[wNlI2PjJzNkC=
NCCIT  NITKPYlHfW6ldHnvckBCe3OjeR?= NGnCcpY4OiCq MmXid4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S17IHHjeIl3cXS7wrC= M4HSOVIzPTZ{MU[w
NCCIT  Ml\TSpVv[3Srb36gRZN{[Xl? NILTdG04OiCq MknGd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiQlHYJIxmfmWu NFnBU5gzOjV4MkG2NC=>
NCCIT  NWDNOpEzTnWwY4Tpc44hSXO|YYm= M{DoVVczKGh? NV64enZLe2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKEKlbD2yJINwdnSnboS= Mn3kNlI2PjJzNkC=
NCCIT  NHThZ|dHfW6ldHnvckBCe3OjeR?= NH2yW|I4OiCq M4iwdZNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBEgXRvYzDs[ZZmdA>? MYGyNlU3OjF4MB?=
HeLa NXPoeGJXTnWwY4Tpc44hSXO|YYm= NHv3Xoc{OC95MDFOwIcwdWx? NE\HUYIzPMLiaB?= MlW1bY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKheDV|78{MRXRONHB{MdMgZY5lyqCJQVTEOFU> NXe0NXlsOjJ2OEe5N|c>
MCF-7  NVHke3ZrTnWwY4Tpc44hSXO|YYm= M17rfVMxNzdyIN88[{9udA>? M4\hS|I1yqCq MmXKbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKheDV|78{MRXRONHB{MdMgZY5lyqCJQVTEOFU> NGnwWGozOjR6N{mzOy=>
HeLa NFHzVpJEgXSxdH;4bYNqfHliQYPzZZk> MlzIN|AwPzBizsznM41t NXHBOXpLOjUEoHi= MYfpcoR2[2W|IHjp[4htgSC|aXfubYZq[2GwdDDs[ZZmdHNib3[g[pJi\22nboTl[EBFVkFicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21? MUmyNlQ5Pzl|Nx?=
MCF-7  M32wb2N6fG:2b4jpZ4l1gSCDc4PhfS=> NHW5bW8{OC95MDFOwIcwdWx? M2XTbFI1yqCq NIKwO4pqdmS3Y3XzJIhq\2iueTDzbYdvcW[rY3HueEBt\X[nbIOgc4Yh\nKjZ33lcpRm\CCGTlGgdoVt\WG|ZTDpcpRwKHSqZTDjfZRweGyjc32= M2r1blIzPDh5OUO3
NT2 M3jiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLxNVAxNTZyMNMg{txoN22u M2qySFI1KGh? MXfJR|UxRTRyMDFCuYcwdWx? M1n6T|IzPDZ7OUWy
NT2 NGPzeWFHfW6ldHnvckBCe3OjeR?= MXS0NFDDqM7:Zz;tcC=> Mn3FNlQhcA>? M{\xZpNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvMzy4MFkh[WO2aY\peJnDqA>? MmPSNlI1Pjl7NUK=
NT2 NXG0OWs{TnWwY4Tpc44hSXO|YYm= MXi0NFDDqM7:Zz;tcC=> NWPwUpljOjRiaB?= Mo[3d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiQlHYJIxmfmWu Mo\HNlI1Pjl7NUK=
NT2 Ml[5SpVv[3Srb36gRZN{[Xl? M3jwSlQxOMLizsznM41t NILneoQzPCCq NVfrRllve2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgRoNtNTJibHX2[Yw> M4DmPFIzPDZ7OUWy
CHO NHnFenNHfW6ldHnvckBCe3OjeR?= MWKyMlXDqM7:Zz;tcC=> MUGxPEBpNzZiZB?= MmDkbY5lfWOnc9MgdIVze2m|dHXuZ4Uhd2ZiY3jyc41we2:vZTDkZY1i\2V? NVXjbXJLOjJ{M{CxPVU>
Jurkat MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M335clAuOTBywrFOwIcwdWx? NFmybGgzPCCq MVLhdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> NWXJWY1SOjJ{MkOzN|I>
Jurkat MonGSpVv[3Srb36gRZN{[Xl? MX[zNOKh|rypL33s NV;Jd4w{OjRiaB?= M2\PUYlv[3KnYYPld{B1cGVicILveIVqdiCuZY\lcJMhd2ZiY4njcIlveyCGMzygRUBidmRiQkG= NGnkNnAzOjJ{M{OzNi=>
Jurkat NFHBRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DTcVAuOTBywrFOwIcwdWx? MlrkNlQhcA>? NY\nUIhycW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigZY4hUUN3MDD2ZYx2\SCxZjCxNFDPxGdxbVy= NGXyPWszOjJ{M{OzNi=>
Jurkat MWXGeY5kfGmxbjDBd5NigQ>? MUizNOKh|rypL33s NV\ON5NVOjRiaB?= Ml;vbY5kemWjc3XzJJRp\SCnZn\lZ5Qhd2ZicInjcollcW:wZTDvckBxcG:|cHjvdplt[XSrb36gcIV3\Wy|IH;mJIhqe3SxbnWgTFJCNlh? MUWyNlIzOzN|Mh?=
U2OS EGFPnls Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorvNE0zyqEQvHevcYw> NX7DVGpvOjRiaB?= MkXVbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MUOyNVgyOTByNx?=
U2OS KuEnls M{n5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvSNE0zyqEQvHevcYw> M3ruXFI1KGh? M1PrV4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NUniXZlNOjF6MUGwNFc>
MCF-7 M2TEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HxSFAuPDByIN88US=> MVK3NkBp MVnMR|UxRTF3MT64xsDPxE1? MV:yNVcxOzJ7MR?=
MCF-7/Adr  MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HQXFAuPDByIN88US=> MnfjO|IhcA>? NUjl[4hIVEN3ME21PE42yqEQvF5CpC=> Mmm2NlE4ODN{OUG=
WI-38 M3;3VWZ2dmO2aX;uJGF{e2G7 NXXnPIlrOC92MD:4NQKBkc7:Zz;tcOKh M1vne|MhcA>? NYnBXYNRcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? MkjZNlE2QTl4MUK=
hBMSC M2fqUWZ2dmO2aX;uJGF{e2G7 NX:1THhbOC92MD:4NQKBkc7:Zz;tcOKh MmLhN{Bp MYrpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg M3LQW|IyPTl7NkGy
NCI-H23 MX;GeY5kfGmxbjDBd5NigQ>? MmHHNE81OC96MPMAje69\y:vbNMg MmrpN{Bp M4\KUolv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> M3G0SlIyPTl7NkGy
A-549 MUTGeY5kfGmxbjDBd5NigQ>? NYTxdHJ4OC92MD:4NQKBkc7:Zz;tcOKh MonrN{Bp NHnkSmFqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh Mk\aNlE2QTl4MUK=
PBL  MVHGeY5kfGmxbjDBd5NigQ>? MmLDNE81OC96MPMAje69\y:vbNMg M4L1eFMhcA>? MkSzbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NFzRUW4zOTV7OU[xNi=>
pol β −/− M3iwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPJO40xNjJ3LUKwNOKh|rypL33s MmXZNlTDqGh? NF7ubYtl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4l1cCCrbnPy[YF{cW6pIHPvcoNmdnS{YYTpc45{yqB? NXHr[HRTOjF{NUG5OFQ>
pol β +/+ M1n2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXIcVMxNjJ3LUKwNOKh|rypL33s NXmyd|BGOjUEoHi= NUDjWWZZ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li MnHRNlEzPTF7NES=
pol β −/− MU\GeY5kfGmxbjDBd5NigQ>? NFLDZVgxNTJwNTFOwIcwdWx? MXSyJIg> MW\jZZV{\XNiRF7BJIRidWGpZR?= Ml\6NlEzPTF7NES=
pol β +/+ M2PafWZ2dmO2aX;uJGF{e2G7 MXmwMVIvPSEQvHevcYw> MXeyJIg> MYDjZZV{\XNiRF7BJIRidWGpZR?= M17CR|IyOjVzOUS0
pol β −/− MYrGeY5kfGmxbjDBd5NigQ>? MkjsNE02KM7:Zz;tcC=> MmjUOFghcA>? M3[1ZYNifXOnczDtbYNzd263Y3zleZMh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MXeyNVI2OTl2NB?=
pol β +/+ NWO2TIZ6TnWwY4Tpc44hSXO|YYm= NF;pVFIxNTVizsznM41t MX60PEBp MnXhZ4F2e2W|IH3pZ5JwdnWlbHX1d{Bld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 M2PTbFIyOjVzOUS0
TK6  NIjP[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXiyOU0yPTBizsznM41t MWO5OkBp NF[3blBqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 Ml\PNlExQDF2OEe=
TK6  sLUC+Apn1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXiyOU0yPTBizsznM41t MoHsPVYhcA>? Mnq5bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M1HIV|IyODhzNEi3
TK6 sAPE1+Apn1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX6XlQzPS1zNUCg{txoN22u MVy5OkBp MlXNd4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7 NF\afFQzOTB6MUS4Oy=>
HCT116 NWn4NHpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXsZ41OOjVvMUWwJO69\y:vbB?= NXm3XVdSQTZiaB?= MoHTbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MUKyNVA5OTR6Nx?=
HCT116 sLUC+Apn1 M32xS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKyOU0yPTBizsznM41t M{TZNlk3KGh? NULJe41qcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M{fUTlIyODhzNEi3
HCT116 sAPE1+Apn1 NYjoe4pqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LNfFI2NTF3MDFOwIcwdWx? MkLzPVYhcA>? NHHxXZZ{cWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= MXOyNVA5OTR6Nx?=

... Click to View More Cell Line Experimental Data

In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

+ Expand
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD-1 mice
  • Formulation: Saline
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
in solvent
Synonyms NSC125066

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 8 2010 Phase 2
NCT00983944 Withdrawn Lymphoma Ohio State University Comprehensive Cancer Center September 2009 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID